management decisions
Decision Dx-SCC PLUS & DecisionDx-SCC ART deliver enhanced accuracy and actionable insights to help guide more informed decisions
Our tests address two critical clinical questions:
What is my patient’s biological risk of regional or distant metastasis as well as local recurrence?
DecisionDx-SCC PLUS is a validated 20 gene expression profile (GEP) test that was uniquely designed to analyze the biological profile of a cutaneous squamous cell carcinoma (cSCC) to identify the risk of regional and distant metastasis as well as local recurrence in patients with cSCC with at least one high-risk feature (high-risk cSCC).
DecisionDx-SCC PLUS uses a proprietary algorithm to integrate tumor biology with specific clinicopathologic risk factors to provide a comprehensive risk assessment for patients with high-risk cSCC. The results deliver personalized risk information to improve risk assessment and help inform key clinical management decisions.
Is my patient likely to benefit from adjuvant radiation therapy (ART)?
DecisionDx-SCC ART is a 40-GEP test that analyzes the biological profile of a cSCC tumor and is independently validated to predict the likelihood of benefit from ART for patients with cSCC with at least one or more high-risk feature.
DecisionDx-SCC ART uses a proprietary algorithm to analyze the personalized gene expression of a tumor to identify patients who are most likely to benefit from ART.
Connect with a representative
